Newsroom
Release archive.
Press releases issued before the April 24, 2026 business combination, under the company’s former name, Coeptis Therapeutics Holdings, Inc. They speak as of their dates. Current news is on the news page.
April 7, 2026PDFCoeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationMarch 9, 2026PDFVanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds BuildFebruary 5, 2026PDFCoeptis Receives Shareholder Approval Towards Z Squared MergerJanuary 6, 2026PDFCoeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z SquaredOctober 1, 2025PDFCoeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes CoverageJuly 22, 2025PDFCoeptis (COEP) Extinguishes Convertible Note with YA II PN, LtdJune 26, 2025PDFCoeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z SquaredMay 28, 2025PDFMonarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in OncologyApril 25, 2025PDFCoeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger AgreementApril 17, 2025PDFCOEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in TechnologyMarch 11, 2025PDFCoeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology PipelineMarch 7, 2025PDFCOEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation PlanFebruary 20, 2025PDFCOEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus NetworkFebruary 20, 2025PDFCOEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate MarketingFebruary 19, 2025PDFCOEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate MarketingFebruary 13, 2025PDFCOEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent StartupsJune 20, 2024PDFCoeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingMay 2, 2024PDFCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingDecember 4, 2023PDFCoeptis Therapeutics to Present at the Emerging Growth ConferenceOctober 31, 2023PDFCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023October 24, 2023PDFCoeptis Therapeutics Announces $2 Million Private PlacementOctober 11, 2023PDFCoeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyOctober 9, 2023PDFCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesOctober 4, 2023PDFCoeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingSeptember 27, 2023PDFCoeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaSeptember 14, 2023PDFCoeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionSeptember 11, 2023PDFCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentAugust 30, 2023PDFCoeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerAugust 17, 2023PDFCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsAugust 1, 2023PDFCoeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticJune 16, 2023PDFCoeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingJune 14, 2023PDFCoeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingJune 9, 2023PDFCoeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketMay 17, 2023PDFCoeptis Therapeutics Appoints Brian Cogley as Chief Financial OfficerMarch 29, 2023PDFCoeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment StrategiesMarch 21, 2023PDFCoeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational MedicineNovember 22, 2022PDFCoeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development ProgramNovember 15, 2022PDFCoeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening BellNovember 8, 2022PDFCoeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" PodcastNovember 2, 2022PDFCoeptis Therapeutics Holdings Expands Board of Directors with New AppointmentsSeptember 21, 2022PDFCoeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T TechnologyMay 17, 2022PDFCoeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid TumorsApril 19, 2022PDFCoeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger AgreementApril 13, 2022PDFCoeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera BiopharmaJanuary 20, 2022PDFCoeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development